FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 687 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Immunotherapy Combination Most Effective as Initial Treatment for BRAF+ Melanoma December 17, 2021 John Cena Set The Record For Most Make-A-Wish Visits And He... March 4, 2019 NF1 Associated with More Cancer Types Than Previously Known April 20, 2021 Foodie Friday: Pumpkin EVERYTHING! October 8, 2021 Load more HOT NEWS ESMO 2022: New Research in Treating Gastrointestinal and Genitourinary Cancers Baby Boy Can’t Stop Smiling After Surgery Allows Him To See... Bariatric Surgery May Reduce the Risk of Some Common Cancers Ensuring a Smooth Leadership Transition at NCI
